Using ferric derisomaltose to improve recovery in gynecologic cancer surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of intravenous ferric derisomaltose in correcting pre-operative iron-deficiency anemia in patients undergoing major surgery for gynecologic cancer. It is a randomized, double-blinded study comparing the treatment to a placebo. The goal is to improve pre-operative hemoglobin levels and reduce the need for blood transfusions, which can carry risks and complications. The trial aims to enroll patients who meet specific criteria related to their surgery and iron levels.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Signed written informed consent prior to initiation of any study specific activities/procedures.
2. Age ≥ 18 years old.
3. Patients undergoing elective major surgery on the gynecologic oncology service with the following criteria will be considered for inclusion:

   1. The indication for the operation may be for suspected or proven gynecologic malignancy.
   2. Major surgery is defined as an operation of a duration of 1 hour or greater, with an Aletti complexity score of at least 1.
   3. The expected time from recruitment to surgery is 28-90 days.
4. Screening haemoglobin less than 120 g/L and transferrin saturation (TSAT) \<20%.
5. Randomization and administration of study infusion a minimum of 21 days and maximum 90 days before planned operation.
6. Negative pregnancy test for women of childbearing potential (WOCBP) (within 7 days prior to treatment).
7. WOCBP must adhere to the contraception requirement from screening throughout the study period until 6 weeks post treatment.
8. Laboratory data used for determination of eligibility (Hemoglobin and Transferrin saturation) at the baseline visit must not be older than 4 weeks.

Exclusion Criteria:

1. Known history of acquired iron overload, or family history of haemochromatosis or thalassemia, or TSAT \>50%.
2. Known alternative cause for anemia (e.g., B12 or folate deficiency, or haemoglobinopathy).
3. Known hypersensitivity to Ferric derisomaltose/iron isomaltoside (Monoferric®) or its excipients.
4. Temperature \>38C or patient on non-prophylactic antibiotics.
5. Known chronic liver disease or active hepatitis.
6. Received erythropoietin or IV iron therapy within previous 12 weeks prior to planned study drug treatment.
7. Alanine transaminase (ALT) or aspartate transaminase (AST) above three times the upper limit of normal (ULN) range.
8. Immunosuppressive therapy (for solid organ transplant), or renal dialysis (current, or planned within next 12 months following treatment with study drug or placebo).
9. Unfit for elective surgery.
10. Pregnancy or lactation.

1\. Unable to fully comprehend and/or perform study procedures and patients with psychiatric illness/social situations/substance abuse that would limit compliance with study requirements.

11\. Cervical cancer with a clinical stage of 2A or greater.

Where it's running

• Arthur J.E. Child Comprehensive Cancer Centre
  Calgary, Alberta, Canada Recruiting

Study contacts

• Study coordinator: Steven Bisch, MD
• Email: Steven.Bisch@ahs.ca
• Phone: 403-521-3721

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• DISC-0974-201 for adults with IBD-related anemia

  This Phase 2 trial will test whether DISC-0974-201 helps adults with inflammatory bowel disease who have anemia driven by inflammation.

  Recruiting at 15 sites Phase 2 Disc Medicine, Inc · Birmingham, Alabama and 14 other locations · NCT07368972

• National registry for people with myelofibrosis and anemia in Germany.

  This project will collect health, treatment, and quality-of-life information from people in Germany with primary or secondary myelofibrosis and anemia to see how their care and symptoms change over time.

  Recruiting iOMEDICO AG · Multiple Locations · NCT06976918

• Evaluating DISC-0974 for treating anemia in myelofibrosis patients

  This study tests if a new treatment called DISC-0974 can help people with myelofibrosis who have anemia feel better and improve their condition.

  Recruiting at 33 sites Phase 1/2 Disc Medicine, Inc · Gilbert, Arizona and 34 other locations · NCT05320198

• NMTCuff vs standard TOF monitoring during gynecologic oncology surgery

  This study tests whether NMTCuff monitoring can better detect neuromuscular recovery than standard TOF monitoring in women undergoing laparoscopic gynecologic cancer surgery.

  Recruiting Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital · Ankara · NCT07925463

• Radiotherapy for gynecologic cancer with up to 10 metastatic sites

  This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.

  Recruiting Affidea Nu-med Center of Oncological DIagnostics and Therapy · Zamość · NCT07883798

• Iron status at ICU discharge in adults with anemia after critical illness

  We are testing whether iron deficiency is common at ICU discharge and whether it relates to how well patients recover after leaving the ICU.

  Recruiting Università degli Studi di Ferrara · Brussels and 3 other locations · NCT07781540

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.